Full growth hormone is a much larger protein with a different structural context. A fragment can't inherit all of its receptor interactions or established clinical uses. When reviewing a paper, record whether the investigators tested the modified sequence, a different terminal fragment or the parent hormone. That distinction determines whether the comparison is relevant.
Representative product imagery. Verify the physical label and lot documentation on receipt.
Metabolic Research
AOD9604
In stock·Ships in 1–2 business days
AOD9604 research material supplied with batch-level documentation. Each unit is labeled with a traceable lot code and links to its corresponding analytical report.
Select size2 options
Select pack sizeSave 18% on kits
1 × 2 mg$37.99
In stockSelected size 2 mgSC-2AD-002
Transparent volume pricing10-vial peptide kits save 18%.
Secure checkout US & EU dispatch
Research use only acknowledgment required at checkout
Published report · Lot 2025256
Reports describe the tested lot. Match the lot on your label before interpreting results.
Compound context
What researchers study
AOD 9604 is a modified peptide fragment associated with the terminal region of human growth hormone. Researchers study its chemistry and metabolic activity in defined experimental systems. This page brings the available research quantities together with the identity questions that matter before a laboratory comparison. It isn't a growth hormone replacement product.
Early published work examined metabolic endpoints in obese Zucker rats. Such experiments can identify a question worth testing, but a rat outcome doesn't establish an effect in people. The AOD-9604 peptide also shouldn't be treated as interchangeable with an unspecified HGH fragment. Sequence differences matter even when two labels refer to the same region of a parent protein.
Lipolysis measurements describe the release of stored lipid components under the conditions of an assay. They don't automatically predict a change in body weight. Cell number, substrate availability and the sampling interval can affect the result. A comparison needs a stated endpoint and a control that distinguishes a metabolic response from a nonspecific loss of viable cells.
Scope limitUse the lot report to confirm the requested sequence and analytical identity. The material is limited to laboratory research. Published experiments do not establish clinical benefits, a human dosage or suitability for injection.
Serenity Compounds is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act.
Common laboratory focus
Sequence documentation should sit beside intact mass and chromatographic results. Disulfide state and related synthesis products can matter for a peptide with this structure. A single large chromatographic peak doesn't settle every structural question. Ask which features the method can distinguish before using purity as the only acceptance criterion.
Study design should connect the proposed mechanism to a measurable outcome. Lipid release in a cell preparation and whole body energy balance are different levels of evidence. Replicates and a suitable reference help establish whether a signal is reproducible. AOD 9604 benefits reported in promotional material still need a source with matching methods.
Quality documentation
Know what your laboratory receives.
Batch records are published for transparency and should be independently reviewed by qualified research personnel.
Current certificateAOD9604 · Lot 2025256Liquilabs s.r.o.View report
- Tamper-evident packaging
- Lot and SKU traceability
- Independent analytical review
Continue exploring
